Small Molecule Inhibition of Dynamin-Dependent Endocytosis Targets Multiple Niche Signals and Impairs Leukemia Stem Cells

Researchers showed that Dynole 34-2, a potent inhibitor of Dynamin GTPase activity, could block transduction of key signaling pathways and overcome chemoresistance of leukemia stem cells.
[Nature Communications]
Tremblay, C. S., Chiu, S. K., Saw, J., McCalmont, H., Litalien, V., Boyle, J., Sonderegger, S. E., Chau, N., Evans, K., Cerruti, L., Salmon, J. M., McCluskey, A., Lock, R. B., Robinson, P. J., Jane, S. M., & Curtis, D. J. (2020). Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells. Nature Communications, 11(1), 6211. https://doi.org/10.1038/s41467-020-20091-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

ZFHX3 Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription

Researchers found that ZFHX3 promoted the proliferation and tumor growth of breast cancer cells in culture and nude mice; and higher expression of ZFHX3 in human breast cancer specimens was associated with poorer prognosis.
[Cancers]
Dong, G., Ma, G., Wu, R., Liu, J., Liu, M., Gao, A., Li, X., A, J., Liu, X., Zhang, Z., Zhang, B., Fu, L., & Dong, J.-T. (2020). ZFHX3 Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription. Cancers, 12(11), 3415. https://doi.org/10.3390/cancers12113415 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Differences and Similarities between Cancer and Somatic Stem Cells: Therapeutic Implications

Understanding the differences in origin, mechanism of self-renewal, and signaling pathways of CSCs and somatic stem cells will provide a better approach to target these specific populations in order to protect healthy cells and minimize side effects.
[Current Stem Cell Research & Therapy]
Rossi, F., Noren, H., Jove, R., Beljanski, V., & Grinnemo, K.-H. (2020). Differences and similarities between cancer and somatic stem cells: therapeutic implications. Stem Cell Research & Therapy, 11(1), 489. https://doi.org/10.1186/s13287-020-02018-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Comprehensive Analysis of Inhibitory Checkpoint Ligand Expression by Glioblastoma Cells

Scientists showed that glioblastoma cells express a large repertoire of inhibitory checkpoint ligands known to control effector T cell responses. Flow cytometry analysis revealed that glioblastoma cells with an enhanced stem cell‐like phenotype express several investigated ligands at significant levels on their cell surface.
[Immunology and Cell Biology]
Robilliard, L. D., Yu, J., Anchan, A., Joseph, W., Finlay, G., Angel, C. E., & Graham, E. S. (n.d.). Comprehensive analysis of inhibitory checkpoint ligand expression by Glioblastoma cells. Immunology & Cell Biology, n/a(n/a). https://doi.org/https://doi.org/10.1111/imcb.12428 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Alpha 1-Antichymotrypsin Contributes to Stem Cell Characteristics and Enhances Tumorigenicity of Glioblastoma

Researchers utilized patient-derived cerebrospinal fluid and primary cultures of glioblastoma brain tumor initiating cells. They determined the impact of SERPINA3 expression in glioma patients using TCGA database. SERPINA3 expression changes were evaluated at both the mRNA and protein levels.
[Neuro-Oncology]
Lara-Velazquez, M., Zarco, N., Carrano, A., Phillipps, J., Norton, E. S., Schiapparelli, P., Alkharboosh, R., Rincon-Torroella, J., Jeanneret, S., Corona, T., Segovia, J., Jentoft, M. E., Chaichana, K. L., Asmann, Y. W., Quinones-Hinojosa, A., & Guerrero-Cazares, H. (n.d.). Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaa264 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Forma Therapeutics Announces Positive Top-Line Olutasidenib Data from a Planned Interim Analysis of a Registrational Phase II Clinical Trial in Acute Myeloid Leukemia

Forma Therapeutics Holdings, Inc. announced positive top-line data from a planned interim analysis of a registrational Phase II clinical trial of olutasidenib, Forma’s selective inhibitor for hematological malignancy cancers with mutations in isocitrate dehydrogenase 1.
[Forma Therapeutics Holdings, Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Imago BioSciences Expands Phase II Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong

Imago BioSciences, Inc. announced the expansion of its global Phase IIb clinical study evaluating bomedemstat for the treatment of advanced myelofibrosis into Hong Kong, where the first patient has now been enrolled and dosed. Myelofibrosis is a rare bone marrow cancer that interferes with the production of blood cells.
[Imago BioSciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Silencing hTERT Attenuates Cancer Stem Cell-Like Characteristics and Radioresistance in the Radioresistant Nasopharyngeal Carcinoma Cell Line CNE-2R

Silencing hTERT suppressed CNE-2R cell proliferation and increased the cell apoptosis rate and radiosensitivity in vitro. Moreover, it could also inhibit the growth of xenografts and increase the apoptosis index and radiosensitivity in vivo.
[Aging]
Aging | Silencing hTERT attenuates cancer stem cell-like characteristics and radioresistance in the radioresistant nasopharyngeal carcinoma cell line CNE-2R - Full Text. (n.d.). Retrieved December 2, 2020, from https://www.aging-us.com/article/104167/text Cite
Full Article
Bookmark

No account yet? Register

0
Share

LncRNA LINC00998 Inhibits the Malignant Glioma Phenotype via the CBX3-Mediated C-Met/Akt/mTOR Axis

Researchers investigated the role of LINC00998 in glioma progression. Through screening using TCGA database, they found that LINC00998 was downregulated in glioblastoma tissues and that low expression of LINC00998 was associated with poor prognosis.
[Cell Death & Disease]
Cai, H., Yu, Y., Ni, X., Li, C., Hu, Y., Wang, J., Chen, F., Xi, S., & Chen, Z. (2020). LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell Death & Disease, 11(12), 1–17. https://doi.org/10.1038/s41419-020-03247-6 Cite
Full Article
Bookmark

No account yet? Register

0
Share

CBL0137 Increases the Targeting Efficacy of Rovalpituzumab Tesirine against Tumor-Initiating Cells in Small Cell Lung Cancer

Researchers investigated the potential effect of combining Rovalpituzumab tesirine and CBL0137 in small cell lung cancer to eradicate tumor-initiating cells more effectively.
[British Journal of Cancer]
Lindner, D. J., Wildey, G., Parker, Y., Dowlati, A., Stark, G. R., & De, S. (2020). CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer. British Journal of Cancer, 1–3. https://doi.org/10.1038/s41416-020-01192-x Cite
Abstract
Bookmark

No account yet? Register

0
Share

Nitric Oxide-Targeted Therapy Inhibits Stemness and Increases the Efficacy of Tamoxifen in Estrogen Receptor-Positive Breast Cancer Cells

Researchers explored whether targeting nitric oxide in estrogen positive breast cancer cells impacts cancer stem cell subpopulation and sensitivity to hormonal therapy with tamoxifen.
[Laboratory Investigation]
López-Sánchez, L. M., Mena, R., Guil-Luna, S., Mantrana, A., Peñarando, J., Toledano-Fonseca, M., Conde, F., De la Haba-Rodríguez, J. R., Aranda, E., & Rodríguez-Ariza, A. (2020). Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells. Laboratory Investigation, 1–12. https://doi.org/10.1038/s41374-020-00507-z Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share